Ironwood Pharmaceuticals (STU:I76) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Ironwood Pharmaceuticals COGS-to-Revenue?

Ironwood Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was €0.0 Mil. Its Revenue for the three months ended in Mar. 2024 was €68.9 Mil.

Ironwood Pharmaceuticals's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ironwood Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

Ironwood Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Ironwood Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ironwood Pharmaceuticals COGS-to-Revenue Chart

Ironwood Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.06

0.01

Ironwood Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Ironwood Pharmaceuticals COGS-to-Revenue Calculation

Ironwood Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	405.988
	=	0.00

Ironwood Pharmaceuticals's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	68.887
	=	0.00

Ironwood Pharmaceuticals (STU:I76) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ironwood Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 68.887
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Ironwood Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ironwood Pharmaceuticals (STU:I76) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (STU:I76) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

IRWD:USA I76:Germany

Address

100 Summer Street, Suite 2300, Boston, MA, USA, 02110

Website

https://www.ironwoodpharma.com

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Ironwood Pharmaceuticals (STU:I76) Headlines

No Headlines